Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Syncrude who wrote (211)	9/10/1999 10:50:00 AM
From: brb	Read Replies (1) \| Respond to of 377

More news, looks like Research Capital has raised their 1 year target price. Post says Vasogen favoured by Research Capital Vasogen Inc VAS Shares issued 33,561,122 1999-09-08 close $2.8 Thursday Sep 9 1999 The Financial Post reports in its Thursday edition that shares of Vasogen fell 30 cents to $2.80 on the Toronto Stock Exchange on Wednesday, on volume of 2.4 million shares. Market Action columnist Stephen Miles notes that the Toronto-based biotechnology firm lost a little altitude after a stellar 32-per-cent jump on Tuesday. The jump came amid speculation that Vasogen will soon begin clinical trials on a compound that could keep organs shut down during surgery from later failing. The treatment is designed to stop the body's immune system from attacking organs during procedures such as open-heart surgery. On Wednesday, Vasogen appointed experienced campaigner Terrance Gregg to its board. Mr. Gregg is president and chief operating officer of MiniMed, a world leader in diabetes management systems. Since 1996, Mr. Gregg has led MiniMed to a 400-per-cent increase in revenue and a 15-fold increase in market capitalization, which now stands at $2.7-billion. Research Capital analyst Rob Millham has a "speculative buy" rating on Vasogen shares, with a 12-month target price of $5.